The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment

The importance of B cells in multiple sclerosis (MS) has been demonstrated through the advent of B-cell-depleting anti-CD20 antibody therapies. Ofatumumab is the first fully human anti-CD20 monoclonal antibody (mAb) developed and tested for subcutaneous (SC) self-administration at monthly doses of 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Stephen L., Kappos, Ludwig, Bar-Or, Amit, Wiendl, Heinz, Paling, David, Williams, Mitzi, Gold, Ralf, Chan, Andrew, Milo, Ron, Das Gupta, Ayan, Karlsson, Goeril, Sullivan, Roseanne, Graham, Gordon, Merschhemke, Martin, Häring, Dieter A., Vermersch, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444716/
https://www.ncbi.nlm.nih.gov/pubmed/37450172
http://dx.doi.org/10.1007/s40120-023-00518-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444716/
https://www.ncbi.nlm.nih.gov/pubmed/37450172
http://dx.doi.org/10.1007/s40120-023-00518-0

Ejemplares similares